Research

Cannabis derivatives | Research and Development

 

Our research and development team at Roth Pharma wants the answers to medical conditions with cannabis derivatives. The right pharmaceutical-grade cannabis  to prevent, treat and manage medical conditions

 

TB

efficacy, accessibility and affordability with cannabis derivatives in combination with two other substances, (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation. Conclusive Prelim Cell Invitro studies

ALZHEIMER

efficacy, accessibility and affordability with marijuana derivatives in combination with other substances, (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation.

CANCER

efficacy, accessibility and affordability with derivatives (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation. Positive conclusive Invitro studies

HIV

efficacy, accessibility and affordability with cannabis derivatives (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation.

RESPIRATORY INFECTIONS

efficacy, accessibility and affordability with cannabis derivatives (cannabinoid/terpenoid, TBA profile, , physiological, pharmacokinetics, pharmacological and clinical evaluation.

DIABETES

efficacy, accessibility and affordability with cannabis derivatives (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation.

REPRODUCTION

efficacy, accessibility and affordability with derivatives (cannabinoid/terpenoid, TBA profile, , physiological, pharmacokinetics, pharmacological and clinical evaluation

OPIOIDS

Focus on the effects of narcotics on physiological regulatory mechanisms of both the BTB and BBB, in particular, the effects of Cannabis, examining the effects of these narcotics on permeability across in vitro models of the BTB and BBB, rates of cell growth, morphology (HRSEM, HRTEM and fluorescence), viability, toxicology, mitochondrial function, apoptosis, ROS and ATP production, protein expression (PCR and Western blotting), etc., on the primary cellular components/cell lines of the BTB and BBB.

EPILEPSY

Refractory epilepsy (LGS) (SMEI-DS) efficacy, accessibility and affordability with derivatives, (cannabinoid/terpenoid profile) evaluating bioavailability (liposome/nano). fMRI. Physiological, pharmacokinetics, pharmacological and clinical evaluation.

FIBROMYALGIA

efficacy, accessibility and affordability with cannabis derivatives (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation.

MALARIA

efficacy, accessibility and affordability with marijuana derivatives (cannabinoid/terpenoid, TBA profile, physiological, pharmacokinetics, pharmacological and clinical evaluation.

PATENT REGISTRATION

Conclusive results have led to a ground breaking patent registration (Details under NDA)

Our research and development team at Roth Pharma wants the answers to medical conditions with cannabis derivatives. The right pharmaceutical-grade cannabis  to prevent, treat and manage medical conditions

Our Competitive Advantage | cannabis derivatives :

  • Strong scientific approach and undertaken research from various departments. With numerous results from agronomy, biochemistry, and clinical evaluation.
  • Research & Development has gained significant knowledge and IP in agronomy and medical science.
  • Crossbreeding has resulted already in chemovars with increased content of selected cannabinoids, increasing efficiency up to 70 times market standards
  • Significant in vitro, animal, and observational research results creating the foundation for clinical trials and extended research efforts.
  • Creation of end-users for buyers and pharmacies through the Pull strategy